TRWR submitted diabetes bioelectronic medicine market approval application to Taiwan FDA

TRWR submitted diabetes bioelectronic medicine market approval application to Taiwan FDA

TRWR submitted diabetes bioelectronic medicine market approval application to Taiwan FDA in April 2022. TRWR’s diabetes bioelectronic medicine is the first application of transcutaneous electrical nerve stimulation as diabetes’s adjunctive treatment. Without predicates, the market approval application review process of our diabetes bioelectronic medicine is based on that of type 3 medical device.